-
Je něco špatně v tomto záznamu ?
Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin
A. Marosi, L. Dufkova, B. Forró, O. Felde, K. Erdélyi, J. Širmarová, M. Palus, V. Hönig, J. Salát, R. Tikos, M. Gyuranecz, D. Růžek, B. Martina, P. Koraka, ADME. Osterhaus, T. Bakonyi,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 2002-01-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 2002-01-01 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2002-01-01 do Před 2 měsíci
Family Health Database (ProQuest)
od 2002-01-01 do Před 2 měsíci
Health Management Database (ProQuest)
od 2002-01-01 do Před 2 měsíci
Public Health Database (ProQuest)
od 2002-01-01 do Před 2 měsíci
- MeSH
- antivirové látky terapeutické užití MeSH
- imunoglobuliny terapeutické užití MeSH
- imunohistochemie MeSH
- Kaplanův-Meierův odhad MeSH
- kvantitativní polymerázová řetězová reakce MeSH
- modely nemocí na zvířatech MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- protilátky virové imunologie MeSH
- replikace viru účinky léků MeSH
- tělesná hmotnost účinky léků MeSH
- virus vztekliny účinky léků imunologie patogenita MeSH
- vzteklina farmakoterapie imunologie MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Recent studies demonstrated that inhibitors of pro-inflammatory molecular cascades triggered by rabies infection in the central nervous system (CNS) can enhance survival in mouse model and that certain antiviral compounds interfere with rabies virus replication in vitro. In this study different combinations of therapeutics were tested to evaluate their effect on survival in rabies-infected mice, as well as on viral load in the CNS. C57Bl/6 mice were infected with Silver-haired bat rabies virus (SHBRV)-18 at virus dose approaching LD50 and LD100. In one experimental group daily treatments were initiated 4 h before-, in other groups 48 or 96 h after challenge. In the first experiment therapeutic combination contained inhibitors of tumour necrosis factor-α (infliximab), caspase-1 (Ac-YVAD-cmk), and a multikinase inhibitor (sorafenib). In the treated groups there was a notable but not significant increase of survival compared to the virus infected, non-treated mice. The addition of human rabies immunoglobulins (HRIG) to the combination in the second experiment almost completely prevented mortality in the pre-exposure treatment group along with a significant reduction of viral titres in the CNS. Post-exposure treatments also greatly improved survival rates. As part of the combination with immunomodulatory compounds, HRIG had a higher impact on survival than alone. In the third experiment the combination was further supplemented with type-I interferons, ribavirin and favipiravir (T-705). As a blood-brain barrier opener, mannitol was also administered. This treatment was unable to prevent lethal consequences of SHBRV-18 infection; furthermore, it caused toxicity in treated mice, presumably due to interaction among the components. In all experiments, viral loads in the CNS were similar in mice that succumbed to rabies regardless of treatment. According to the findings, inhibitors of detrimental host response to rabies combined with antibodies can be considered among the possible therapeutic and post-exposure options in human rabies cases.
Artemis One Health Research Foundation Delft The Netherlands
Department of Virology Veterinary Research Institute Hudcova 70 CZ 62100 Brno Czech Republic
Viroscience Lab Erasmus Medical Centre Wytemaweg 80 3015CN Rotterdam The Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025723
- 003
- CZ-PrNML
- 005
- 20230815111822.0
- 007
- ta
- 008
- 201125s2019 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.vaccine.2018.05.066 $2 doi
- 035 __
- $a (PubMed)29805091
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Marosi, András $u Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Hungária krt. 23 - 25, 1143 Budapest, Hungary. Electronic address: Marosi.Andras@univet.hu.
- 245 10
- $a Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin / $c A. Marosi, L. Dufkova, B. Forró, O. Felde, K. Erdélyi, J. Širmarová, M. Palus, V. Hönig, J. Salát, R. Tikos, M. Gyuranecz, D. Růžek, B. Martina, P. Koraka, ADME. Osterhaus, T. Bakonyi,
- 520 9_
- $a Recent studies demonstrated that inhibitors of pro-inflammatory molecular cascades triggered by rabies infection in the central nervous system (CNS) can enhance survival in mouse model and that certain antiviral compounds interfere with rabies virus replication in vitro. In this study different combinations of therapeutics were tested to evaluate their effect on survival in rabies-infected mice, as well as on viral load in the CNS. C57Bl/6 mice were infected with Silver-haired bat rabies virus (SHBRV)-18 at virus dose approaching LD50 and LD100. In one experimental group daily treatments were initiated 4 h before-, in other groups 48 or 96 h after challenge. In the first experiment therapeutic combination contained inhibitors of tumour necrosis factor-α (infliximab), caspase-1 (Ac-YVAD-cmk), and a multikinase inhibitor (sorafenib). In the treated groups there was a notable but not significant increase of survival compared to the virus infected, non-treated mice. The addition of human rabies immunoglobulins (HRIG) to the combination in the second experiment almost completely prevented mortality in the pre-exposure treatment group along with a significant reduction of viral titres in the CNS. Post-exposure treatments also greatly improved survival rates. As part of the combination with immunomodulatory compounds, HRIG had a higher impact on survival than alone. In the third experiment the combination was further supplemented with type-I interferons, ribavirin and favipiravir (T-705). As a blood-brain barrier opener, mannitol was also administered. This treatment was unable to prevent lethal consequences of SHBRV-18 infection; furthermore, it caused toxicity in treated mice, presumably due to interaction among the components. In all experiments, viral loads in the CNS were similar in mice that succumbed to rabies regardless of treatment. According to the findings, inhibitors of detrimental host response to rabies combined with antibodies can be considered among the possible therapeutic and post-exposure options in human rabies cases.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protilátky virové $x imunologie $7 D000914
- 650 _2
- $a antivirové látky $x terapeutické užití $7 D000998
- 650 _2
- $a tělesná hmotnost $x účinky léků $7 D001835
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a imunoglobuliny $x terapeutické užití $7 D007136
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a vzteklina $x farmakoterapie $x imunologie $7 D011818
- 650 _2
- $a virus vztekliny $x účinky léků $x imunologie $x patogenita $7 D011820
- 650 _2
- $a kvantitativní polymerázová řetězová reakce $7 D060888
- 650 _2
- $a replikace viru $x účinky léků $7 D014779
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Dufkova, Lucie $u Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic.
- 700 1_
- $a Forró, Barbara $u Institute for Veterinary Medical Research, Centre for Agricultural Research, Hungarian Academy of Sciences, Hungária krt. 21, 1143 Budapest, Hungary.
- 700 1_
- $a Felde, Orsolya $u Institute for Veterinary Medical Research, Centre for Agricultural Research, Hungarian Academy of Sciences, Hungária krt. 21, 1143 Budapest, Hungary.
- 700 1_
- $a Erdélyi, Károly $u National Food Chain Safety Office, Veterinary Diagnostic Directorate, Tábornok u. 2, 1149 Budapest, Hungary.
- 700 1_
- $a Širmarová, Jana $u Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic.
- 700 1_
- $a Palus, Martin $u Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic.
- 700 1_
- $a Hönig, Václav, $d 1982- $u Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic. $7 jcu2012681186
- 700 1_
- $a Salát, Jiří $u Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic.
- 700 1_
- $a Tikos, Réka $u Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Hungária krt. 23 - 25, 1143 Budapest, Hungary.
- 700 1_
- $a Gyuranecz, Miklós $u Institute for Veterinary Medical Research, Centre for Agricultural Research, Hungarian Academy of Sciences, Hungária krt. 21, 1143 Budapest, Hungary.
- 700 1_
- $a Růžek, Daniel, $u Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ-37005 Ceske Budejovice, Czech Republic. $d 1981- $7 stk2008441707
- 700 1_
- $a Martina, Byron $u Artemis One Health Research Foundation, Delft, The Netherlands.
- 700 1_
- $a Koraka, Penelope $u Viroscience Lab, Erasmus Medical Centre, Wytemaweg 80 3015CN, Rotterdam, The Netherlands.
- 700 1_
- $a Osterhaus, Albert D M E $u Artemis One Health Research Foundation, Delft, The Netherlands; Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover, Germany.
- 700 1_
- $a Bakonyi, Tamás $u Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Hungária krt. 23 - 25, 1143 Budapest, Hungary; Viral Zoonoses, Emerging and Vector-Borne Infections Group, Institute of Virology, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, Austria.
- 773 0_
- $w MED00004631 $t Vaccine $x 1873-2518 $g Roč. 37, č. 33 (2019), s. 4724-4735
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29805091 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20230815111819 $b ABA008
- 999 __
- $a ok $b bmc $g 1599868 $s 1116409
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 37 $c 33 $d 4724-4735 $e 20180524 $i 1873-2518 $m Vaccine $n Vaccine $x MED00004631
- LZP __
- $a Pubmed-20201125